November 1, 2011 – Claret Medical Inc. said its Montage System has received CE mark approval as the world's first complete system of filtration to protect both carotid arteries simultaneously. The 6 French catheter is delivered via radial or brachial access, providing complete neuro protection during intravascular procedures such as transcatheter aortic valve intervention (TAVI). The unique design of the Montage System not only provides neuro-protection from debris, but also captures and removes potential stroke-causing embolic material from the body.

November 1, 2011 – Boston Scientific released the schedule of its major events and product-related clinical research for the Cardiovascular Research Foundation's (CRF) 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, scheduled for Nov. 7-11 in San Francisco. TCT is designed to provide new insights for physicians who treat patients with cardiovascular disease and other vascular health issues.

November 1, 2011 – Volcano Corp., a developer and manufacturer of intravascular diagnosis and therapy guidance tools, said revenues for the third quarter of 2011 increased 18 percent versus the third quarter of 2010.

Philips TruFlight Select is its first economical positron emission tomography/computed tomography (PET/CT) system equipped premium time-of-flight (TOF) technology, Astonish TF.  Competitive systems with similar performance can cost up to $500,000 more than the TruFlight Select PET/CT.

November 1, 2011 – Boston Scientific introduced its CardioTeach iPad app, an industry-first, free educational resource to help healthcare professionals better educate patients and caregivers about therapy options related to cardiovascular and peripheral diseases, specifically atrial and ventricular arrhythmias, coronary artery disease, heart failure, heart rhythm disorders and peripheral vascular disease.

November 1, 2011 – CardioComm Solutions, a provider of hardware and software solutions for cardiovascular health management, announced the extension of their current OEM agreement with GE Healthcare.  The agreement renewal means both companies will continue to play a role in the expanding cardiovascular monitoring and diagnostic devices segment, forecast recently by MarketResearch.com to grow a compound annual growth rate (CAGR) of 5 percent between now and 2017.    

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now